HIV/AIDS Therapy
CXCR4 inhibitor AMD3100 has side effects/does not decrease HIV viral load
Published in AIDS Weekly, December 27th, 2004
According to a study from the United States, "AMD3100 is a CXCR4 receptor inhibitor with anti-HIV-1 activity in vitro. We tested the safety, pharmacokinetics and antiviral effect of AMD3100 administered for 10 days by continuous intravenous infusion in an open-label dose escalation study front 2.5 to 160 mug/kg/hour.
"Forty HIV-infected patients with an HIV RNA level >5000 copies/ml- on stable antiretroviral (ARV) regimens or off therapy were enrolled. Syncytium-inducing (SI) phenotype in an MT-2 cell assay was required in higher dose cohorts. Most...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2004-12-27)
More Articles from AIDS Weekly
- Antiretroviral Monitoring
Therapeutic drug monitoring simplified for twice-daily lopinavir/ritonavir - Drug Monitoring
Automated LC/LC-MS rapidly analyses samples for therapeutic drug monitoring - HIV/AIDS Therapy
Risk of virologic failure with LPV/r increased in children pretreated with PIs - HIV/AIDS-Associated Lipodystrophy
Interleukin-18 linked to HIV-associated lipodystrophy - HIV/AIDS-Related Infection
Fine-needle aspiration cytology in TBL differs between HIV+ and HIV- patients - Collaborations
Pharma firm, Chinese university inaugurate HIV/AIDS public health program - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
